Protagenic Therapeutics, Inc.

NasdaqCM:PTIX Stock Report

Mkt Cap: US$9.7m

Protagenic Therapeutics Financial Health

How is Protagenic Therapeutics's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: PTIX's short term assets ($8.3M) exceed its short term liabilities ($553.5K).

Long Term Liabilities: PTIX's short term assets ($8.3M) exceed its long term liabilities ($318.8K).


Debt to Equity History and Analysis

Debt Level: PTIX has more cash than its total debt.

Reducing Debt: PTIX's debt to equity ratio has increased from 0% to 4.3% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PTIX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: PTIX has sufficient cash runway for 2.8 years if free cash flow continues to reduce at historical rates of 15.9% each year.


Discover healthy companies